Short answer
Esperion Therapeutics, Inc. (ESPR) filed an 8-K current report with the SEC on June 16, 2026 reporting Item 8.01 (Other Events). HSR antitrust waiting period expired June 15, 2026, removing a key regulatory closing condition.
Esperion Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- HSR antitrust waiting period expired June 15, 2026, removing a key regulatory closing condition
- Merger with ArchiMed affiliate remains contingent on customary conditions, including stockholder approval
- Special stockholder meeting scheduled for July 8, 2026 at 8:00 a.m. Eastern Time
- Transaction completion risk remains from termination rights, litigation, regulatory matters, and unmet closing conditions
- CVR holders may receive no payments if net sales milestones are not achieved
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Esperion Therapeutics, Inc. 8-K filings
Get the next ESPR 8-K as it lands
Follow ESPR for push alerts, or ask the research agent what this filing means.